Cryoport Dirección
Dirección controles de criterios 3/4
El CEO de Cryoport es Jerry Shelton , nombrado en Nov 2012, tiene una permanencia de 13.5 años. compensación anual total es $2.38M, compuesta por 40.7% salario y 59.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.44% de las acciones de la empresa, por valor de $17.31M. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 11.9 años, respectivamente.
Información clave
Jerry Shelton
Chief Executive Officer (CEO)
US$2.4m
Compensación total
| Porcentaje del salario del CEO | 40.74% |
| Permanencia del CEO | 13.5yrs |
| Participación del CEO | 2.4% |
| Permanencia media de la dirección | 6.3yrs |
| Promedio de permanencia en la Junta Directiva | 11.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.
Actualización de narrativa • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.Actualización de narrativa • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.Actualización de narrativa • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.Actualización de narrativa • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).Actualización de narrativa • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).Actualización de narrativa • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).Actualización de narrativa • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.Actualización de narrativa • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.Actualización de narrativa • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.Actualización de narrativa • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.Actualización de narrativa • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.Actualización de narrativa • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.Actualización de narrativa • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.Artículo de análisis • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...Artículo de análisis • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...Artículo de análisis • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Nueva narrativa • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.Artículo de análisis • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...Artículo de análisis • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...Artículo de análisis • Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...Artículo de análisis • Jul 22
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Artículo de análisis • Jun 25
Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Cryoport, Inc. ( NASDAQ:CYRX ) share price has dived 28% in the last thirty...Artículo de análisis • Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
It's not a stretch to say that Cryoport, Inc.'s ( NASDAQ:CYRX ) price-to-sales (or "P/S") ratio of 3.7x right now seems...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$45m |
| Dec 31 2025 | US$2m | US$968k | -US$42m |
| Sep 30 2025 | n/a | n/a | -US$48m |
| Jun 30 2025 | n/a | n/a | -US$38m |
| Mar 31 2025 | n/a | n/a | -US$104m |
| Dec 31 2024 | US$2m | US$921k | -US$113m |
| Sep 30 2024 | n/a | n/a | -US$158m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$117m |
| Dec 31 2023 | US$2m | US$866k | -US$93m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$2m | US$792k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$296m |
| Jun 30 2022 | n/a | n/a | -US$297m |
| Mar 31 2022 | n/a | n/a | -US$293m |
| Dec 31 2021 | US$5m | US$713k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$78m |
| Mar 31 2021 | n/a | n/a | -US$77m |
| Dec 31 2020 | US$5m | US$613k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$23m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$4m | US$600k | -US$18m |
Compensación vs. Mercado: La compensación total de Jerry($USD2.38M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD3.73M).
Compensación vs. Ingresos: La compensación de Jerry ha aumentado mientras la empresa no es rentable.
CEO
Jerry Shelton (80 yo)
13.5yrs
Permanencia
US$2,375,524
Compensación
Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 13.5yrs | US$2.38m | 2.44% $ 17.3m | |
| Senior VP | 14.9yrs | US$1.12m | 0.55% $ 3.9m | |
| Senior VP and Chief Digital & Technology Officer | 2.3yrs | US$1.09m | 0.22% $ 1.5m | |
| Senior VP & Chief Scientific Officer | 5.7yrs | US$986.06k | 0.20% $ 1.4m | |
| Vice President of Corporate Development & Investor Relations | no data | sin datos | sin datos | |
| VP, General Counsel & Corporate Secretary | no data | sin datos | sin datos | |
| Vice President of Global Human Resources & Organizational Development | no data | sin datos | sin datos | |
| Chief Operating Officer of Cryoport Systems | 6.3yrs | sin datos | sin datos |
6.3yrs
Permanencia media
63yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CYRX es experimentado (6.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 13.6yrs | US$2.38m | 2.44% $ 17.3m | |
| Senior VP and Chief Digital & Technology Officer | 12.7yrs | US$1.09m | 0.22% $ 1.5m | |
| Independent Director | 5.2yrs | US$421.79k | 0.11% $ 812.6k | |
| Member of Commercial Advisory Board | 13.3yrs | sin datos | sin datos | |
| Independent Director | 10.7yrs | US$419.07k | 0.10% $ 721.4k | |
| Independent Director | 5.6yrs | US$70.00k | sin datos | |
| Member of Advisory Board | 18.3yrs | sin datos | sin datos | |
| Member of Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 11.9yrs | US$430.97k | 0.11% $ 809.6k | |
| Independent Director | 7.3yrs | US$395.07k | 0.12% $ 826.0k |
11.9yrs
Permanencia media
66.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CYRX son experimentados ( 11.9 años antigüedad media).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 04:55 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cryoport, Inc. está cubierta por 14 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |